Your browser version may not work well with NCBI's Web applications. More information here...
1: J Neuroimmunol. 2007 Nov;191(1-2):26-38. Epub 2007 Nov 1.Click here to read Links

Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system.

Neuroimmunology Research Centre, School of Medicine, The University of Queensland, Australia. m.hawes@uq.edu.au

The elimination of autoreactive T cells from the central nervous system (CNS) by apoptosis plays an important role in switching off autoimmune attack. B-cell apoptosis in the CNS probably also has a key role in downregulating autoimmunity. Augmenting lymphocyte apoptosis in the CNS is a potential strategy for treating autoimmune CNS diseases such as multiple sclerosis. These strategies involve modulation of the physiological pro-apoptotic and anti-apoptotic pathways that control lymphocyte fate in the CNS. In the case of T cells, apoptosis can be augmented by enhancing activation-induced T-cell apoptosis through the CD95 (Fas) pathway and by inhibiting costimulation-induced anti-apoptotic pathways mediated through BCL-2 and BCL-X L.

PMID: 17931708 [PubMed - indexed for MEDLINE]